A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

781

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Post-Menopausal Osteoporosis
Interventions
DRUG

ibandronate [Bonviva/Boniva]

3 mg IV every 3 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).

DRUG

ibandronate [Bonviva/Boniva]

2 mg IV every 2 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).

Trial Locations (39)

1036

Budapest

1180

Brussels

1399

Copenhagen

2139

St Leonards

2750

Ballerup Municipality

3129

Sydney

4010

Stavanger

4020

Liège

5507

Haugesund

7100

Vejle

7129

Sommerset West

7500

Cape Town

8000

Aarhus

9000

Aalborg

11000

Mexico City

12200

Berlin

16011

Arenzano

20354

Hamburg

28046

Madrid

30501

Gainesville

37067

Valeggio sul Mincio

45032

Orléans

45276

Essen

53100

Siena

53792

Madison

58103

Fargo

58501

Bismarck

63110

St Louis

64460

Monterrey

68131

Omaha

69000

Lyon

305 99

Pilsen

128 00

Prague

0176

Oslo

86-300

Grudziądz

30-510

Krakow

31-501

Krakow

Unknown

Pretoria

AB25 2ZD

Aberdeen

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00551174 - A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment | Biotech Hunter | Biotech Hunter